Canine CD20 / MS4A1 Full Length Protein, His Tag (Detergent)
Product Sizes
20 ug
£1425.00
CD0-C52H5-20UG
100 ug
£3680.00
CD0-C52H5-100UG
500 ug
£8319.00
CD0-C52H5-500UG
About this Product
- SKU:
- CD0-C52H5
- Buffer:
- 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5
- Extra Details:
- B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
- Immunogen:
- CD20
- Molecular Weight:
- 35.2 kda
- Physical State:
- Liquid
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- -70[o]C
- Supplier:
- ACRO Biosystems
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
